Summary
Overview
Work History
Education
Skills
Additional Information
Publication
Presentations at Scientific Meetings and Symposiums
Timeline
Generic

Yu (Lucy) Cong

Https://www.linkedin.com/in/yu-lucy-cong-47822215/,Potomac, MD

Summary

20+ Years Expert with 48 publications in high-consequence pathogens. Renowned for impactful studies on Nipah virus, Lassa virus, yellow fever virus, and SARS-CoV-2. Expertise in interdisciplinary team leadership and collaborations with top pharmaceutical companies and government agencies. Adaptive to viral challenges, notably addressing SARS-CoV-2 variants. Leading collaborative studies and animal research, specializing in characterizing host responses to infection. Utilizing diverse approaches and advanced imaging for therapeutic and vaccine development across various animal models.

Overview

28
28
years of professional experience

Work History

ASSOCIATE SUPERVISOR/STUDY DIRECTOR

Laulima Government Solutions
03.2020 - Current
  • Administer and coordinate day-to-day operations, laboratory layout, equipment, and SOPs for BSL-2/BSL-4 virology labs at IRF under Viral Pathogenesis and Assessment Branch.
  • Provide recommendations on hiring scientific staff, ensuring a skilled and efficient team.
  • Act as Principal Investigator, proposing new science collaborations at IRF leadership meetings, and designing/renewing animal study protocols to fulfill client goals and meet regulatory requirements.
  • Interact with committees and functional groups to progress study plans from inception through approval to implementation and conclusion.
  • Serve as point of contact for external collaborators, leading and coordinating collaborative projects with scientists from other institutions.
  • Lead interdisciplinary team, including graduate-level virologists, immunologists, histopathologists, physicists, and imaging scientists, in developing and characterizing in vivo animal models for studying pathogenesis of various high-consequence pathogens.
  • Act as internal reviewer for abstracts, manuscripts, and proposals from collaborators.
  • Participate in meetings of organizations such as WHO, NIAID, and SAVE during COVID-19 pandemic.
  • Efficiently plan, execute, and report on scientific activities in accordance with division directives, presenting research findings at national/international conferences and publishing in high-quality peer-reviewed scientific journals.

Accomplishments and Achievements:

Leading NiV Viral Replicon Particle (VRP) Safety and Efficacy Evaluation in NHP Model: Led a highly prioritized project in collaboration with CDC/DARPA evaluating the safety and efficacy of Nipah Viral Replicon Particle (VRP) in non-human primates (NHPs) to advance this vaccine toward clinical trials. Demonstrated the safety and efficacy of the VRP via intranasal vaccination.

Development of Nipah Disease Model in African Green Monkeys (AGM): Led, directed, and conducted two NiV NHP model development/characterization studies in collaboration with NIAID Rocky Mountain laboratory (RML). Successfully developed the NHP model to recapitulate encephalitic manifestations observed in human NiV disease. This research has likely shed light on the mechanisms underlying Nipah virus-induced neurological disease and has potential implications for treatment strategies. Working on generating and compiling data, with expected publication of 5-6 additional papers.

Lassa NHP Study Achievement: Led a groundbreaking Lassa NHP study with six rhesus monkeys exposed to LASV via intramuscular administration. Assessment of clinical, virological, immunological, imaging, and histopathological endpoints resulted in two surviving monkeys and the development of new audiometry capabilities at IRF-Frederick. This achievement, making IRF-Frederick the first to conduct tympanometry and pure-tone audiometry in the NHP model, drew attention from WHO, CEPI, and NIH, leading to invitations for presentations. Ongoing manuscript preparation reflects the study's significant contribution to Lassa fever research.

COVID-19 Response and Hamster Studies:

  • Played a pivotal role in COVID-19 response, leading over thirty SARS-CoV-2 hamster studies supporting OWS/CAG, NIAID/DMID/BARDA, U.S. HHS Response, and global pharmaceutical collaborators.
  • Utilized advanced imaging for small animal model development, publishing works on testing efficacy of a panel of therapeutic antibody candidates, including nearly all clinically available & EUA nAb therapeutics from SAb, CELLTRION, VIR, BOEHRINGER INGELHEIM, Lilly, IAVI, RU, REGENERON, AstraZeneca, Grifols, emergent, molecular partners. Data from these studies contributing to the understanding of potential treatments for COVID-19.
  • Led studies characterizing several variants, collaborating with pharmaceutical companies worldwide, and providing crucial data for human clinical trials.
  • Led the characterization study of three SARS-CoV-2 stocks for human experimental infection trials on hamsters in support of NIH NIAID DMID.
  • Led a hamster study in collaboration with Columbia University, testing two llama-derived nanobody constructs. Demonstrated effectiveness of both constructs as therapeutics against SARS-CoV-2 Alpha and Delta variants.
  • Led IRF-Frederick collaboration with NIAID’s Dr. Joshua Tan to evaluate efficacy of therapeutic treatment candidates against SARS-CoV-2 WA01 isolate and other variants in hamster model. More than 10 monoclonal antibody candidates were evaluated for clinical support and data obtained from these studies have been published in Science, Cell Host Microbe and Science Translated Medicine. Most recent manuscript is pending submission to Nature Medicine.

Associate Study Implementer/Research Scientist

Battelle Memorial Institute
06.2017 - 03.2020
  • Acted as the Principal Investigator (PI) and Study Manager, ensuring satisfaction for both internal and external clients.
  • Originated and steered study plans through the complex approval process, overseeing their successful execution from conception to completion.
  • Led multi-disciplinary teams to conduct comprehensive in vivo animal studies for evaluating medical countermeasures against high-consequence pathogens like Ebola, Nipah, and Marburg viruses.
  • Ensured rapid and effective data analysis, providing timely and accurate results to collaborators, and contributed significantly to scientific publications and conference presentations.


Accomplishments and Achievements:

  • Successfully completed a guinea pig study to determine biomarkers of MARV disease progression through serial imaging using 18F-FDG PET/CT. This innovative approach measured lymphoid activation in the spleen, showcasing increased metabolic activity post-infection. Currently engaged in study close-out and manuscript preparation.
  • Led and implemented two NHP studies, resulting in the full development of a Nipah neurological disease model in African Green Monkeys (AGM). This comprehensive model characterizes both immunological and physiological (MRI/CT) aspects of the host response to infection, a novel contribution with imaging data already published in JID.
  • Collaborated with Cornell University to confirm virulence for Hendra virus and mouse-adapted Ebola virus in hamsters. Evaluated the vaccine efficacy of a multivalent pseudotyped VSV against HeV, NiV, or EBOV infection in hamsters, leading to a publication in npj vaccine.
  • Manuscript preparation as a corresponding author summarizing variable conditions tested during the development of high-throughput cell-based drug screen assays. These assays, designed to identify compounds with anti-Ebola virus activity, utilized established cell lines and human primary cells. The study emphasizes the importance of guidelines for testing drugs in vitro and generating reproducible data sets, contributing to a recent publication in PLOS ONE.

SURPPORT SCIENTIST/RESEARCHER

Battelle Memorial Institute
04.2012 - 06.2017

Accomplishments and Achievements:

  • Developed and refined method for isolating and purifying macrophages and dendritic cells from both human and non-human primate blood cells. This method has been successfully used for large-scale drug screening against severe pathogens, making IRF unique institution.
  • Studied antigen presentation and host cell immunity regulation following yellow fever virus infection in both human and primate cells, resulting in primary-authored publications.
  • Assessed antiviral activity of HIV drugs against Ebola in both lab settings and animal models, with published results in collaboration with CDC.
  • Investigated antiviral efficacy of FDA-approved drugs against MERS-CoV in human cells, leading to primary-authored publication.
  • Explored Nipah virus disease progression in monkeys, publishing findings on immune response and changes in cell populations.
  • Conducted advanced immunological assays, including Ebola ADCC study using flow cytometry.
  • Contributed to generation and characterization of institutional virus stocks.
  • Operated flow cytometry for various studies and assisted in research collaborations across departments.
  • Played key role in developing scientific designs, writing SOPs, and training junior staff.
  • Cross-trained IRF staff in primary cell preparation and regularly presented research data in meetings and conferences.

FDA ORISE FELLOW

ORISE
12.2010 - 04.2012

Accomplishments and Achievements:

  • Successfully identified predictive gene markers associated with neurotoxicity in mumps virus vaccine strains.
  • Pioneered construction of chimeric recombinant viruses, merging genes from attenuated and wild-type mumps virus strains. Conducted thorough assessments in established animal model, leading to identification of key genes and gene regions involved in neuroattenuation. This groundbreaking work has been published.
  • Investigated impact of genetic heterogeneity within virus population, contributing valuable insights to field.
  • Effectively presented research data to supervisor and actively participated in manuscript preparation.
  • Established and implemented laboratory SOPs, showcasing commitment to precision and consistency. Drafted comprehensive technical reports, assays, and reagent qualification documents.
  • Played key role in maintaining overall lab organization, including equipment upkeep and calibration. Demonstrated adept management of assay materials and reagent inventories, ensuring cost-effective operations.

POSTDOCTORAL FELLOW

University Of Texas At San Antonio
10.2003 - 06.2010

Accomplishments and Achievements:

  • Employed advanced and conventional immunologic assays to characterize immune responses for vaccine candidates against Francisella tularensis, contributing to tularemia vaccine development funded by NIH R01.
  • Investigated immune responses post-immunization with defined F. tularensis subsp. novicida mutant, ∆iglB, advancing understanding of its potential as live attenuated vaccine for pneumonic tularemia.
  • Conducted comprehensive oral vaccination mechanism study for ∆iglB, enhancing insights into its mode of action through oral administration.
  • Established umanized animal model for chlamydial genital tract infection, enabling identification of antigens and study of host immune responses relevant to human chlamydial disease in mice.
  • Developed effective vaccination regimen using CPAF antigen with Th1 adjuvant (CpG), providing protection against persistent chlamydial vaginal infection in mice.
  • Contributed valuable insights into innate immune mechanisms against Francisella infection by demonstrating roles of mast cells and IL-4.
  • Assumed full responsibility for technical and project completion goals, including literature review, experiment execution, project and data analysis.
  • Authored research and safety SOPs, submitted monthly reports to NIH, met administrative deadlines, and presented and published research findings in journals.
  • Managed laboratory operations and regulated Select Agents in BSL-3 facilities, overseeing acquisitions and inventory of bacterial isolates.

RESEARCH ASSISTANT PROFESSOR/RESERCH ASSOCIATE

Division Of Viral Hepatitis, IVDC/China CDC
10.1995 - 10.2003

Accomplishments and Achievements:

  • Played pivotal role in sequencing complete genome of China Beijing strain of Hepatitis G virus (HGV), first-time achievement, with data deposited in Genbank.
  • Developed molecular diagnostic techniques for clinical and epidemiological surveillance of HGV in China, contributing significantly to understanding and monitoring of virus.
  • Successfully identified and expressed three HGV NS5 recombinant proteins, enhancing antigenicity and sensitivity of HGV ELISA diagnostic kits.
  • Established various transgenic mouse models to study pathogenesis and immunology of HCV structural and NS3 proteins, providing valuable insights into mechanisms underlying virus.
  • Authored comprehensive grants and proposals, showcasing proficiency in securing funding for research endeavors.
  • Reviewed scientific journal papers, staying actively engaged with latest developments in field.
  • Instructed and mentored laboratory students in immunology, microbiology, and cell biology courses, contributing to education and development of next generation of scientists.
  • Demonstrated technical troubleshooting skills and managed ordering and inventory of consumable supplies and reagents, ensuring smooth operation of laboratory activities.

Education

Master of Science - Immunology

Peking Union Medical College (PUMC)
Beijing, China
07.2001

Bachelor of Clinical Medicine (MD Equivalent) - Clinical Medicine

Jinzhou Medical University
Jinzhou, Liaoning, China
07.1995

Skills

Project Management and Leadership

Collaborative Research and Team Coordination

Scientific Writing and Communication

Grant and Proposal Preparation

Regulatory Compliance and Ethical Practices

Mentorship and Training

Peer Reviewer for Scientific Journals

Global Health Impact

Strategic Planning

Multidisciplinary Research Integration

Technical skills:

Virology: virus growth, propagation, quantitation, plaque assay, neutralization assays

Immunology techniques: multicolor flow cytometry, multicolor panel design, FACS data analysis (Diva, flowjo and cytobank softwares), ELISA, ELISPOT, IFA, magnetic sorting, multiplex cytokine bead array, monoclonal antibody production

Molecular biology: DNA/RNA extraction and quantification (RT-PCR, qPCR), gene cloning and reverse genetics technique, gene and protein expression

Histology and pathology: H&E staining, IHC

Vaccine development

Primary cell culture including immune subsets

Animal model development and characterization

GLP regulations and procedures

BSL-4 & BSL-3 Biocontainment Pathogen Research

Additional Information

Professional Training 2012-present

Biosafety level (BSL)-4 Certification by NIH


Security Approvals 2012-present

Select Agent Program Approval by CDC

Access National Agency Check and Inquiries (ANACI) by NIH


AWARDS


2022 NIAID Merit Award December 2022

Awarded as a member of the NIAID/DCR/IRF COVID-19 Team.

Received in recognition of outstanding accomplishments, selected by Anthony S. Fauci, M.D.


Contract Research Conference Travel Grant Award February 2016

Awarded by Battelle Memorial Institute for presentation at the 30th International Conference on Antiviral Research (ICAR) at La Jolla, CA, April 17-21, 2016.

Publication

Yu Cong, Saurabh Dixit, Erin Kollins, Russ M. Byrum, Donna L. Perry, Lou M. Huzella, Sanae Lembirik, Anthony Marketon, Scott M. Anthony, David Drawbaugh, Elizabeth Eudy, Michael Murphy, Jiro Wada, Anya Crane, Ann Eakin, Karl Erlandson, Connie Schmaljohn, and Michael R. Holbrook. Characterization and Evaluation of the Efficacy of Therapeutic Antibodies for the Prevention of SARS-CoV-2 Variant of Concerns Infection and Disease in the Hamster Model. (pending submission to cell report medicine)

Peer-reviewed and preprint publications

Postnikova, E., Liang, J., Yu, S., Cai, Y., Cong, Y., Holbrook, M.R. (2023). Anti-Nipah Virus Enzyme-Linked Immunosorbent Assays with Non-human Primate and Hamster Serum. In: Freiberg, A.N., Rockx, B. (eds) Nipah Virus. Methods in Molecular Biology, vol 2682. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3283-3_17

Cong Y, Lee JH, Perry DL, Cooper K, Wang H, Dixit S, Liu DX, Feuerstein IM, Solomon J, Bartos C, Seidel J, Hammoud DA, Adams R, Anthony SM, Liang J, Schuko N, Li R, Liu Y, Wang Z, Tarbet EB, Hischak AMW, Hart R, Isic N, Burdette T, Drawbaugh D, Huzella LM, Byrum R, Ragland D, St Claire MC, Wada J, Kurtz JR, Hensley LE, Schmaljohn CS, Holbrook MR, Johnson RF. Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models. Antiviral Res. 2023 Jun;214:105605. doi: 10.1016/j.antiviral.2023.105605. Epub 2023 Apr 15. PMID: 37068595; PMCID: PMC10105383.

Cong Y, Mucker E, Perry D, Dixit S, Kollins E, Byrum R, Huzella L, Kim R, Josleyn M, Kwilas S, Stefan C, Shoemaker C, Koehler J, Coyne S, Delp K, Liang J, Drawbaugh D, Hischak A, Hart R, Holbrook MR. (2023). Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters. Antiviral Research. 213. 105589. 10.1016/j.antiviral.2023.105589.

Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, Bangar AS, Imbiakha B, Upadhye V, Liang J, Ma A, Bradel-Tretheway B, Kaza B, Yeo YY, Choi EJ, Johnston GP, Huzella L, Kollins E, Dixit S, Yu S, Postnikova E, Ortega V, August A, Holbrook MR, Aguilar HC. Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses. NPJ Vaccines. 2022 Dec 17;7(1):166. doi: 10.1038/s41541-022-00588-5. PMID: 36528644; PMCID: PMC9759047.

Wang H, Seidel J, Bartos C, Byrum R, Sayre PJ, Cooper K, Cong Y, Kim DY, Calcagno C, Kuhn JH, Crane A, Wada J, Johnson RF, Hammoud DA, Lee JH. Intramuscular [18F]F-FDG Administration for Successful PET Imaging of Golden Hamsters in a Maximum Containment Laboratory Setting. Viruses. 2022 Nov 11;14(11):2492. doi: 10.3390/v14112492. PMID: 36423101; PMCID: PMC9695137.

Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe. 2023 Jan 11;31(1):97-111.e12. doi: 10.1016/j.chom.2022.10.010. Epub 2022 Nov 7. PMID: 36347257; PMCID: PMC9639329.

Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper A, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J. (2022). Broadly neutralizing antibodies target the coronavirus fusion peptide. Science. 377. 10.1126/science.abq3773.

Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper A, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J. Broadly neutralizing antibodies target the coronavirus fusion peptide. bioRxiv [Preprint]. 2022 Apr 12:2022.04.11.487879. doi: 10.1101/2022.04.11.487879. Update in: Science. 2022 Jul 12;:eabq3773. PMID: 35441178; PMCID: PMC9016638.

Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv [Preprint]. 2021 Apr 1:2021.04.01.437942. doi: 10.1101/2021.04.01.437942. Update in: Sci Transl Med. 2021 Oct 20;13(616):eabj5413. PMID: 33821267; PMCID: PMC8020967.

Syed M.S. Reza, Dara Bradley, Nina Aiosa, Marcelo Castro, Ji Hyun Lee, Byeong-Yeul Lee, Richard S. Bennett, Lisa E. Hensley, Yu Cong, Reed Johnson, Dima Hammoud, Irwin Feuerstein, Jeffrey Solomon, Deep Learning for Automated Liver Segmentation to Aid in the Study of Infectious Diseases in Nonhuman Primates, Academic Radiology, 2020, ISSN 1076-6332, https://doi.org/10.1016/j.acra.2020.08.023.

Ji Hyun Lee, Dima A Hammoud, Yu Cong, Louis M Huzella, Marcelo A Castro, Jeffrey Solomon, Joseph Laux, Matthew Lackemeyer, J Kyle Bohannon, Oscar Rojas, Russ Byrum, Ricky Adams, Danny Ragland, Marisa St Claire, Vincent Munster, Michael R Holbrook (2019). The Use of Large-Particle Aerosol Exposure to Nipah Virus to Mimic Human Neurological Disease Manifestations in the African Green Monkey, The Journal of Infectious Diseases, jiz502, https://doi.org/10.1093/infdis/jiz502

Abigail Lara, Yu Cong, Peter B. Jahrling, Mark Mednikov, Elena Postnikova, Shuiqing Yu, Vincent Munster, Michael R. Holbrook (2019). Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol. PLoS Negl Trop Dis 13(6): e0007454. https://doi.org/10.1371/ journal.pntd.0007454

James Logue, Walter Vargas Licona, Timothy K. Cooper, Becky Reeder, Russel Byrum, Jing Qin, Nicole Deiuliis Murphy, Yu Cong, Amanda Bonilla, Jennifer Sword, Wade Weaver, Gregory Kocher, Gene G. Olinger, Peter B. Jahrling, Lisa E. Hensley and Richard S. Bennett (2019). Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice. Viruses 2019, 11, 161; doi:10.3390/v11020161

Dima A. Hammoud, Margaret R. Lentz, Abigail Lara, Jordan K. Bohannon, Irwin Feuerstein, Louis Huzella, Peter B. Jahrling, Matthew Lackemeyer, Joseph Laux, Oscar Rojas, Philip Sayre, Jeffrey Solomon, Yu Cong, Vincent Munster, Michael R. Holbrook (2018). Aerosol exposure to intermediate size Nipah virus particles induces neurological disease in African green monkeys. PLoS Negl Trop Dis 12(11): e0006978. https://doi.org/10.1371/journal. pntd.0006978

Julie Dyall, Joshua C. Johnson, Brit J. Hart, Elena Postnikova, Yu Cong, Huanying Zhou, Dawn M. Gerhardt, Julia Michelotti, Anna N. Honko, Steven Kern, Lisa Evans DeWald, Kathleen G. O’Loughlin, Carol E. Green, Jon C. Mirsalis, Richard S. Bennett, Gene G. Olinger Jr., Peter B. Jahrling, Lisa E. Hensley. In Vitro and In Vivo Activity of Amiodarone against Ebola Virus. J Infect Dis. 2018 Jul 16. doi: 10.1093/infdis/jiy345

Lisa Evans DeWald, Julie Dyall, Jennifer M. Sword, Lisa Torzewski, Huanying Zhou, Elena Postnikova, Erin Kollins, Isis Alexander, Robin Gross, Yu Cong, Dawn M. Gerhardt, Reed F. Johnson, Gene G. Olinger Jr., Michael R. Holbrook, Lisa E. Hensley, and Peter B. Jahrling (2018). The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. J Infect Dis. 2018 Jul 4. doi: 10.1093/infdis/jiy332

Yu Cong, Brit J. Hart, Robin Gross, Huanying Zhou, Laura Bollinger, Jiro Wada, Lisa E. Hensley, Peter B. Jahrling, Julie Dyall, Michael R. Holbrook. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells (2018). MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen presenting cells. PLoS ONE 13(3): e0194868. https://doi.org/10.1371/journal.pone.0194868

Elena Postnikova*, Yu Cong*#, Lisa Evans DeWald, Shuiqing Yu, Brit J. Hart, Julie Dyall, Huanying Zhou, Robin Gross, James Logue, Yingyun Cai, Nicole Deiuliis, Julia Michelotti, Anna Honko, Richard Bennett, Michael R. Holbrook, Gene G. Olinger, Jr, Lisa E. Hensley, Peter B. Jahrling. Testing therapeutics in cell-based assays: factors that influence the apparent potency of drugs. PLoS ONE 13(3): e0194880. https://doi.org/10.1371/journal.pone.0194880 (*Equal contribution authors, #Corresponding author)

Pramila Walpita*, Yu Cong*, Peter B. Jahrling, Oscar Rojas, Elena Postnikova, Shuiqing Yu, Lisa Johns and Michael. R. Holbrook (2017). A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. npj Vaccines (2017) 2:21; doi:10.1038/s41541-017-0023-7 (*Equal contribution authors)

Cong Y, Lentz MR, Lara A, Alexander I, Bartos C, et al. (2017). Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus. PLOS Neglected Tropical Diseases 11(4): e0005532. doi: 10.1371/journal.pntd.0005532

Julie Dyall, Brit J. Hart, Elena Postnikova, Yu Cong, Huanying Zhou, Dawn M. Gerhardt, Denise Freeburger, Julia Michelotti, Anna N. Honko, Lisa Evans DeWald, Richard S. Bennett, Gene G. Olinger, Jr, Peter B. Jahrling, Lisa E. Hensley (2017). Interferon-beta and Interferon-gamma Are Weak Inhibitors of Ebola Virus in Cell-based Assays. J Infect Dis 2017 jix134. doi: 10.1093/infdis/jix134

Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, et al. (2016). Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS ONE 11(11): e0166318.doi:10.1371/journal.pone.0166318

Cong Y, McArthur MA, Cohen M, Jahrling PB, Janosko KB, Josleyn N, et al. (2016) Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells. PLoS Negl Trop Dis 10(5): e0004709. doi:10.1371/journal. pntd.0004709

Christian J. Sauder, Vahan Simonyan, Laurie Ngo, Konstantinos Karagiannis, Yu Cong, Cheryl Zhang, Rong Wang, Wells W. Wu, Tahir Malik, Steven A. Rubin. Evidence that a polyhexameric genome length is preferred, but not strictly required, for efficient mumps virus replication. Virology 2016 2016 Jun; 493:173-88.doi: 10.1016/j.virol.2016.03.021. Epub 2016 Apr 6.

Christian J Sauder, Laurie Ngo, Vahan Simonyan, Yu Cong, Cheryl Zhang, Malen Link, Tahir Malik, Steven Rubin. Generation and propagation of recombinant mumps viruses exhibiting an additional U residue in the homopolymeric U tract of the F gene-end signal. Virus Genes (2015) 51:12–24 DOI 10.1007/s11262-015-1204-y

Yu Cong, Jieh-Juen Yu, M. Neal Guentzel, Michael T. Berton, Janakiram Seshu, Karl E. Klose, Bernard P. Arulanandam. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (∆iglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine 27 (2009) 5554–5561.

Heather J. Powell, Yu Cong, Jieh-Juen Yu, M. Neal Guentzel, Michael T. Berton, Karl E. Klose, Ashlesh K. Murthy, Bernard P. Arulanandam. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clinical and Vaccine Immunology, 2009 Apr;16(4):444-52.

Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.

Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 8; 105(27): 9313-8.

Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.

Jiao HY, Zhan MY, Yi Y, Cong Y, Tian RG, Zhang WY, Bi SL. Expression of human IL-12 in mammalian cell and study on its biological activities. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Sep; 21(3):235-7.

Murthy AK*, Cong Y*, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006 Dec; 74(12):6722-9. (*Equal contribution authors)

Bai Y, Xia GL, Guo Y, Cong Y, Jia ZY, Guo MZ, Zhao HL, Zhan MY. Influence of the mutants of hepatitis B surface antigen on the cell immunity. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Jun; 19(2):124-7.

BAI Yu, XIA Guo-Liang, JIA Zhi-Yuan, CONG Yu, WANG Xiao-Li, GUO Min-Zhuo, ZHAN Mei-yun, Antigenic Analysis of the Common Recombinant Mutate Types of HBsAg, Chinese J. Exp. Clin. Virol, 2003, 17(1):31-34.

Yu Cong, Hongyuan Jiao, Meiyun Zhan, et al, Expression and Antigenicity Analysis of Hepatitis G Virus NS5 Gene. Chinese J. Exp. Clin. Virol., 2002, 16(2): 150-153.

Xia Guo-liang, Cong Yu, Wang Xiao-li. Inactivated Hepatitis A Aaccine HavrixTM: Immunogenicity, Efficacy, Safety and Recommendations. Chinese Journal of Vaccines & Immunization, 2002, (128): 378-381.

Wenjie Tan, Gang Chen, Ningshao Xia, He Huang, Yu Cong, Ji Miao,Meiyun Zhan. Cloning and Sequence Analysis of Hepatitis G Virus in Partial NS5 Region Isolated from Two Henan’s Blood Donor. Chinese Journal of Virology, 1999, 14(2): 114-119.

Wang Hailin, Chen Hongsong, Xia Ningshao, Tan Wenjie, Chen Gang, Liu Yulan, Cong Yu, Sun Jing, Zeng Ding, Hou Yunde, Wang Yu, Zhan Meiyun, cDNA Cloning and Sequence Analysis of Hepatitis G Virus Genome Isolated from a Chinese Blood Donor. Chinese Medical Journal. 1999, 112 (8): 747-749.

Yu Cong, Wenjie Tan, Meiyun Zhan. Detection of Hepatitis G Virus (HGV) Infection Among Clinical Patients with Hepatitis/Liver Diseases in China by Reverse Transcription-nested Polymerase Chain Reaction (RT-PCR). Chinese J Exp Clin Virol, 1998，12 (2):173-175.

Wenjie Tan, Yu Cong, Shengli Bi, Meiyun Zhan. DNA-based Immunization for the Induction of Humoral Response Against the Hepatitis C Virus Nucleocapsid in Mice. Chinese Journal of Immunology, 1998, 14(6), 453-455.

Wenjie Tan, Zhenwei Lang, Yu Cong, Meiyun Zhan. Transgenic Expression of Hepatitis C Virus Core and NS3 Proteins in the Mouse is not Cytopathic. Chinese Journal of Virology, 1998，14(4):302-306.

Shengdong Liao, Yu Cong, Meiyun Zhan. Observed Change of Clinic and Enzymes in Patients with Virai Hepatitis G. Chinese J. Exp. Clin. Virol., 1998，12(4):333-335.

Wenjie Tan, Ningshao Xia, Yu Cong, Meiyun Zhan. Identification of Hepatitis C or/and G Virus RNA in One Tube by Reverse Transcription Nested Polymerase Chain Reaction. Chinese J. Exp. Clin. Virol., 1998, 12(2):176-178.

Miao Ji, Cong Xu, Tan Wenjie, Cong Yu, Chen Gang, Zhan Meiyun. Rapid Construction of Recombinant Baculovirus Carrying Hepatitis B Virus Surface Antigen Gene by Using a Novel Baculovirus Shuttle Vector (Bacmid). Chinese J. Exp. Clin. Virol., 1998，12(3):245-248.

Wenjie Tan, Gang Chen, Guangsan Li, Ye Liu, Yu Cong, Meiyun Zhan. Production of Three Transgenic Mouse Lineages Which Simultaneously Carries Structural Gene and/or Non-Structural Gene 3 (NS3) Region of Hepatitis C Virus. Acta of Biochemistry and Biophysics in China, 1998，25 (3),279-282.

Ji Miao, Wenjie Tan, Xu Cong, Yu Cong, Gang Chen, Shengli Bi, Meiyun Zhan. Expression and Processing of Structural Ployprotein of Chinese Hepatitis C Virus Expressed in Insect Cells. Chinese Journal of Virology, 1998，14 (4):289-295.

Wenjie Tan, Yu Cong, Guangsan Li. Transgenic Mice from Fertilized Eggs microinjected with Hepatitis C Virus Structural Genes. Chinese Journal of Virology, 1997, 13 (1):19-23.

Wenjie Tan, Zhenwei Lang, Yu Cong, Meiyun Zhan. Core Protein of Hepatitis C Virus Expressed in the Transgenic Mice is Associated with the Expression of Fas Molecular. Chinese Journal of Experimental and Clinical Virology, 1997, 11(3):205-207.

PRESENTATIONS AT SCIENTIFIC MEETINGS AND SYMPOSIUMS

Yu Cong, Jonathan Kurtz, 1. Saurabh Dixit, Louis M Huzella, Matthew Lackemeyer, Russell Byrum, Marisa St. Claire, Vincent Munster, Michael R Holbrook. Discrepancy Between Immune Response of Green Monkey Survivors and Those That Succumbed After Large-Particle Aerosol Exposure to Nipah Virus Malaysia Strain (NiVM). 2024 Viruses. 2024 Feb 14-16; Barcelona, Spain

Yu Cong, Saurabh Dixit, Timothy K. Cooper, Louis M. Huzella, Matthew Lackemeyer, Erin Kollins, Russell Byrum, Steven Mazur, Byeong Yeul Lee, Philip Sayre, Joseph Laux, Jeffrey Solomon, Marcelo Castro, Sanae Lembirik, David Drawbaugh, Kyra Hadley, Claudia Calcagno, Dima Hammoud, Jiro Wada, Anya Crane, Marisa St. Claire, Vincent Munster, Michael R. Holbrook. Comparison of Disease Induced by Large-Particle Aerosol Exposure to Malaysia and Bangladesh Strains of Nipah Virus in African Green Monkeys. ASTMH [American Society of Tropical Medicine & Hygiene] 72nd Annual Meeting; 2023 Oct 18–22; Chicago, Illinois, USA.

Yu Cong, Saurabh Dixit, Erin Kollins, Eliza W. Choi, Russell Byrum, Lou M. Huzella, Donna L. Perry, Elena Postnikova, Amit Ranjan, Lokendrasingh V. Chauhan, David Drawbaugh li, Kyra Hadley, Kelly Wetzel, Marisa St. Claire, W. Ian Lipkin, Lisa E. Hensley, Connie S. Schmaljohn, Michael R. Holbrook and Thomas Briese. Pre-Clinical Efficacy of Nanobodies as Passive Immunotherapeutics in the Golden Hamster Model of SARS-COV-2 Infection. 36th International Conference on Antiviral Research (ICAR), 13-17 MARCH 2023, Virtual Meeting.

Yu Cong, Saurabh Dixit, Erin Kollins, Russ M. Byrum, Donna L. Perry, Lou M. Huzella, Sanae Lembirik, Anthony Marketon, Scott M. Anthony, David Drawbaugh, Elizabeth Eudy, Michael Murphy, Jiro Wada, Anya Crane, Ann Eakin, Karl Erlandson, Connie Schmaljohn, and Michael R. Holbrook. Characterization and Evaluation of the Efficacy of Therapeutic Antibodies for the Prevention of SARS-CoV-2 (Omicron) Infection and Disease in the Hamster Model. ASTMH 71th annual meeting, October 30- November 3, 2022, Seattle, WA, USA and Jan 30th 2023, NCI Winter Research Symposium.

Characterization of SARS-CoV-2-Induced Disease in Young, Aged, and hACE2 Golden Hamsters by CT and 18F-FDG PET. 2022 Spring Research Festival.

Yu Cong, Ann Eakin, Karl Erlandson, Connie Schmaljohn and Michael R. Holbrook. Assessment of therapeutic antibodies for the prevention of SARS-CoV-2 infection and disease in the hamster model. Submitted for 2022 Keynote abstract.

Yu Cong, Ji Hyun Lee, Irwin M. Feuerstein, Dima Hammoud, Jurgen Seidel, Jeffrey Solomon, Hui Wang, Marcelo Castro, Christopher Bartos, Kurt Cooper, Louis Huzella, David X. Liu, Donna Perry, Amanda M.W. Hischak, Nejra Isic, Ricky Adams, Tracey Burdette, Janie Liang, Saurabh Dixit, Nicolette Schuko, Rong Li, Yanan Liu, Zhongde Wang, Bart Tarbet, Russell Byrum, Danny R. Ragland, Marisa St. Claire, Travis Warren, Connie Schmaljohn, Lisa E. Hensley, Michael R. Holbrook. SARS-CoV-2 Infection in Aged Golden Hamsters Leads to Severe Pulmonary Disease and Recapitulates Severe Human COVID-19 Disease. ASTMH 70th Annual Meeting, November 17-21, 2021, Virtual Meeting.

Characterization of SARS-CoV-2 Induced Disease in Golden Syrian Hamsters by CT and 18F-FDG PET. NIAID investigator call, Sep 1, 2020.

Yu Cong, Dima Hammoud, Louis Huzella, Ji Hyun Lee, Matthew Lackemeyer, Jonathan Kurtz, Adams Ricky, Vincent Munster and Michael R Holbrook. Development of a nonhuman primate (NHP) model that recapitulates human Nipah virus disease when animals are exposed to a large particle aerosol of Nipah virus. 33rd International Conference on Antiviral Research (ICAR). Seattle, WA, March 30 to April 3, 2020.

Yu Cong, Brit J. Hart, Robin Gross, Huanying Zhou, Lisa E. Hensley, Peter B. Jahrling, Julie Dyall, Michael R. Holbrook. MERS-CoV infection of human monocyte-derived cells and antiviral efficacy of select FDA-approved drugs. 30th International Conference on Antiviral Research (ICAR). Atlanta, GA, May 21-25, 2017.

Yu Cong, Julie Dyall, Brit J. Hart, Elena Postnikova, Huanying Zhou, Dawn Traynor, Julia Michelotti, Lisa Evans DeWald, Pamela J. Glass, Michael R. Holbrook, Richard S Bennett, Gene G. Olinger Jr., Anna N. Honko, Lisa E. Hensley, Peter B. Jahrling. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus In Vitro and In Vivo. 29th International Conference on Antiviral Research (ICAR). La Jolla, CA, April 17-21, 2016.

Yu Cong, Michael R. Holbrook. Yellow fever virus infection of human and non-human primate monocyte-derived dendritic cells and macrophages. American Society for Virology 32nd Annual Meeting, 2014 (Penn State University Park), July 2013.

Y. Cong, J.-J. Yu, M.N. Guentzel, K.E. Klose, B.P. Arulanandam. The Efficacy of Oral Vaccination with a Defined Francisella Vaccine Strain in Inducing Protective Immunity against Pheumonic Tularemia. 6th International Conference on Tularemia 13 - 16 Sep 2009. Charité Campus Mitte-Berlin.

Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Trachomatis Infection, FOCIS Conference, Boston, May 2005.

Yu Cong, Hongyuan Jiao, Meiyun Zhan. Expression and Antigenicity Analysis of Hepatitis G Virus NS5 Protein. J of Gastroenterology and Hepatology. 2001, 16（Suppl.）A297: P-105.

Yu Cong, Wenjie Tan, Meiyun Zhan. Detection of Hepatitis G Virus (HGV) Infection Among Clinical Patients with Hepatitis/Liver Diseases in China by Reverse Transcription-nested Polymerase Chain Reaction (RT-PCR). J of Gastroenterologyand Hepatology, 1997, 12 (Suppl.) s146.

Presentations at Scientific Meetings and Symposiums

Yu Cong, Jonathan Kurtz, 1. Saurabh Dixit, Louis M Huzella, Matthew Lackemeyer, Russell Byrum, Marisa St. Claire, Vincent Munster, Michael R Holbrook. Discrepancy Between Immune Response of Green Monkey Survivors and Those That Succumbed After Large-Particle Aerosol Exposure to Nipah Virus Malaysia Strain (NiVM). 2024 Viruses. 2024 Feb 14-16; Barcelona, Spain

Yu Cong, Saurabh Dixit, Timothy K. Cooper, Louis M. Huzella, Matthew Lackemeyer, Erin Kollins, Russell Byrum, Steven Mazur, Byeong Yeul Lee, Philip Sayre, Joseph Laux, Jeffrey Solomon, Marcelo Castro, Sanae Lembirik, David Drawbaugh, Kyra Hadley, Claudia Calcagno, Dima Hammoud, Jiro Wada, Anya Crane, Marisa St. Claire, Vincent Munster, Michael R. Holbrook. Comparison of Disease Induced by Large-Particle Aerosol Exposure to Malaysia and Bangladesh Strains of Nipah Virus in African Green Monkeys. ASTMH [American Society of Tropical Medicine & Hygiene] 72nd Annual Meeting; 2023 Oct 18–22; Chicago, Illinois, USA.

Yu Cong, Saurabh Dixit, Erin Kollins, Eliza W. Choi, Russell Byrum, Lou M. Huzella, Donna L. Perry, Elena Postnikova, Amit Ranjan, Lokendrasingh V. Chauhan, David Drawbaugh li, Kyra Hadley, Kelly Wetzel, Marisa St. Claire, W. Ian Lipkin, Lisa E. Hensley, Connie S. Schmaljohn, Michael R. Holbrook and Thomas Briese. Pre-Clinical Efficacy of Nanobodies as Passive Immunotherapeutics in the Golden Hamster Model of SARS-COV-2 Infection. 36th International Conference on Antiviral Research (ICAR), 13-17 MARCH 2023, Virtual Meeting.

Yu Cong, Saurabh Dixit, Erin Kollins, Russ M. Byrum, Donna L. Perry, Lou M. Huzella, Sanae Lembirik, Anthony Marketon, Scott M. Anthony, David Drawbaugh, Elizabeth Eudy, Michael Murphy, Jiro Wada, Anya Crane, Ann Eakin, Karl Erlandson, Connie Schmaljohn, and Michael R. Holbrook. Characterization and Evaluation of the Efficacy of Therapeutic Antibodies for the Prevention of SARS-CoV-2 (Omicron) Infection and Disease in the Hamster Model. ASTMH 71th annual meeting, October 30- November 3, 2022, Seattle, WA, USA and Jan 30th 2023, NCI Winter Research Symposium.

Characterization of SARS-CoV-2-Induced Disease in Young, Aged, and hACE2 Golden Hamsters by CT and 18F-FDG PET. 2022 Spring Research Festival.

Yu Cong, Ann Eakin, Karl Erlandson, Connie Schmaljohn and Michael R. Holbrook. Assessment of therapeutic antibodies for the prevention of SARS-CoV-2 infection and disease in the hamster model. Submitted for 2022 Keynote abstract.

Yu Cong, Ji Hyun Lee, Irwin M. Feuerstein, Dima Hammoud, Jurgen Seidel, Jeffrey Solomon, Hui Wang, Marcelo Castro, Christopher Bartos, Kurt Cooper, Louis Huzella, David X. Liu, Donna Perry, Amanda M.W. Hischak, Nejra Isic, Ricky Adams, Tracey Burdette, Janie Liang, Saurabh Dixit, Nicolette Schuko, Rong Li, Yanan Liu, Zhongde Wang, Bart Tarbet, Russell Byrum, Danny R. Ragland, Marisa St. Claire, Travis Warren, Connie Schmaljohn, Lisa E. Hensley, Michael R. Holbrook. SARS-CoV-2 Infection in Aged Golden Hamsters Leads to Severe Pulmonary Disease and Recapitulates Severe Human COVID-19 Disease. ASTMH 70th Annual Meeting, November 17-21, 2021, Virtual Meeting.

Characterization of SARS-CoV-2 Induced Disease in Golden Syrian Hamsters by CT and 18F-FDG PET. NIAID investigator call, Sep 1, 2020.

Yu Cong, Dima Hammoud, Louis Huzella, Ji Hyun Lee, Matthew Lackemeyer, Jonathan Kurtz, Adams Ricky, Vincent Munster and Michael R Holbrook. Development of a nonhuman primate (NHP) model that recapitulates human Nipah virus disease when animals are exposed to a large particle aerosol of Nipah virus. 33rd International Conference on Antiviral Research (ICAR). Seattle, WA, March 30 to April 3, 2020.

Yu Cong, Brit J. Hart, Robin Gross, Huanying Zhou, Lisa E. Hensley, Peter B. Jahrling, Julie Dyall, Michael R. Holbrook. MERS-CoV infection of human monocyte-derived cells and antiviral efficacy of select FDA-approved drugs. 30th International Conference on Antiviral Research (ICAR). Atlanta, GA, May 21-25, 2017.

Yu Cong, Julie Dyall, Brit J. Hart, Elena Postnikova, Huanying Zhou, Dawn Traynor, Julia Michelotti, Lisa Evans DeWald, Pamela J. Glass, Michael R. Holbrook, Richard S Bennett, Gene G. Olinger Jr., Anna N. Honko, Lisa E. Hensley, Peter B. Jahrling. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus In Vitro and In Vivo. 29th International Conference on Antiviral Research (ICAR). La Jolla, CA, April 17-21, 2016.

Yu Cong, Michael R. Holbrook. Yellow fever virus infection of human and non-human primate monocyte-derived dendritic cells and macrophages. American Society for Virology 32nd Annual Meeting, 2014 (Penn State University Park), July 2013.

Y. Cong, J.-J. Yu, M.N. Guentzel, K.E. Klose, B.P. Arulanandam. The Efficacy of Oral Vaccination with a Defined Francisella Vaccine Strain in Inducing Protective Immunity against Pheumonic Tularemia. 6th International Conference on Tularemia 13 - 16 Sep 2009. Charité Campus Mitte-Berlin.

Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Trachomatis Infection, FOCIS Conference, Boston, May 2005.

Yu Cong, Hongyuan Jiao, Meiyun Zhan. Expression and Antigenicity Analysis of Hepatitis G Virus NS5 Protein. J of Gastroenterology and Hepatology. 2001, 16（Suppl.）A297: P-105.

Yu Cong, Wenjie Tan, Meiyun Zhan. Detection of Hepatitis G Virus (HGV) Infection Among Clinical Patients with Hepatitis/Liver Diseases in China by Reverse Transcription-nested Polymerase Chain Reaction (RT-PCR). J of Gastroenterologyand Hepatology, 1997, 12 (Suppl.) s146.

Timeline

ASSOCIATE SUPERVISOR/STUDY DIRECTOR

Laulima Government Solutions
03.2020 - Current

Associate Study Implementer/Research Scientist

Battelle Memorial Institute
06.2017 - 03.2020

SURPPORT SCIENTIST/RESEARCHER

Battelle Memorial Institute
04.2012 - 06.2017

FDA ORISE FELLOW

ORISE
12.2010 - 04.2012

POSTDOCTORAL FELLOW

University Of Texas At San Antonio
10.2003 - 06.2010

RESEARCH ASSISTANT PROFESSOR/RESERCH ASSOCIATE

Division Of Viral Hepatitis, IVDC/China CDC
10.1995 - 10.2003

Master of Science - Immunology

Peking Union Medical College (PUMC)

Bachelor of Clinical Medicine (MD Equivalent) - Clinical Medicine

Jinzhou Medical University

Similar Profiles

  • Lola Spence

    Lola SpenceLola Spence

    Cashier/Advisor at Laulima HawiCashier/Advisor at Laulima Hawi

  • Kelly Burch

    Kelly BurchKelly Burch

    Child and Youth Program Assistant at Laulima Child Development CenterChild and Youth Program Assistant at Laulima Child Development Center

  • Aleecia Smith

    Aleecia SmithAleecia Smith

    Child Caregiver at Laulima Child Development centerChild Caregiver at Laulima Child Development center

  • ANUBHAV MISHRA

    ANUBHAV MISHRAANUBHAV MISHRA

    Senior Research Associate (Study Director) at Aarsh Centre for Research and DevelopmentSenior Research Associate (Study Director) at Aarsh Centre for Research and Development

  • Roberto Torres, DHA

    Roberto Torres, DHARoberto Torres, DHA

    Associate Director, Study Lead Country Operations at AstraZeneca Alexion Rare DiseasesAssociate Director, Study Lead Country Operations at AstraZeneca Alexion Rare Diseases

CREATE PROFILE
Yu (Lucy) Cong